TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07701954: A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single Doses of LCA-0061 in Atopic Healthy Participants

Sponsor: Lycia Therapeutics, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07701954 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07701954 Rescue Dossier →